2 ml tirzepatide vial Zepbound 2.5 mg/0.5 injection (single-dose vial) Images Buy Mounjaro Vial 2.5/0.5 (Tirzepatide)

Suspected ontogeny of a recently described hypo-androgenic PCOS-like phenotype with advancing age

In 2024 the Food and Drug Administration added cardiovascular risk as a reason to be prescribed the GLP-1 drug Wegovy, grounded in results from a major trial that showed fewer heart attacks, strokes, and cardiovascular deaths in adults with obesity or overweight and established heart disease

Importantly, patients with chronic kidney disease (CKD) may require lower protein intake and should consult with their healthcare provider or a nephrologist before increasing protein consumption

Patient-First Approach We believe that semaglutide therapy is most successful when patients feel heard, supported, and empowered